TRUSCREEN GROUP LIMITED — Investor Relations & Filings

TruScreen Group Limited specializes in the development and manufacture of medical technology for cervical cancer screening. The company's primary product is the TruScreen cervical cancer screening system, an objective, real-time diagnostic tool. Unlike traditional cytology-based methods such as Pap smears, which require laboratory infrastructure and specialized personnel, the TruScreen device utilizes opto-electrical tissue sensing technology to identify precancerous and cancerous changes in the cervix. The system works by measuring the electrical and optical responses of cervical tissue, providing an immediate result at the point of care. This non-invasive approach eliminates the need for tissue sampling and subsequent laboratory processing. The technology is designed to improve screening accessibility by offering a portable and cost-effective alternative to conventional screening programs.